Biotech · Private company
JCR Pharmaceuticals Co., Ltd.
Track this companyFree. Adds JCR Pharmaceuticals Co., Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials64 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- IdursulfasePhase 3 · Mucopolysaccharidosis IIClinicalTrials.gov · fetched Nov 12, 2026
- JR-141Phase 3 · Mucopolysaccharidosis IIClinicalTrials.gov · fetched Nov 12, 2026
- JR-141 or IdursulfasePhase 3 · Mucopolysaccharidosis IIClinicalTrials.gov · fetched Nov 12, 2026
- JR-171Phase 2 · Mucopolysaccharidosis IClinicalTrials.gov · fetched Nov 12, 2026
- JR-171 (lepunafusp alfa)Phase 2 · Mucopolysaccharidosis IClinicalTrials.gov · fetched Nov 12, 2026
- JR-446Phase 2 · Mucopolysaccharidosis IIIBClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)PHASE1_PHASE2 · RECRUITING · started Sep 9, 2026ClinicalTrials.gov NCT07640984 · fetched Nov 12, 2026
- A Long-Term Observational Study of Patients With FucosidosisRECRUITING · started Mar 25, 2026ClinicalTrials.gov NCT07615400 · fetched Nov 12, 2026
- An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) SubjectsPHASE3 · ENROLLING_BY_INVITATION · started Feb 22, 2023ClinicalTrials.gov NCT05594992 · fetched Nov 12, 2026
- A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)PHASE3 · ACTIVE_NOT_RECRUITING · started Feb 14, 2022ClinicalTrials.gov NCT04573023 · fetched Nov 12, 2026
- An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)PHASE1_PHASE2 · COMPLETED · started Oct 28, 2021ClinicalTrials.gov NCT04453085 · fetched Nov 12, 2026
- A Study of JR-171 in Patients With Mucopolysaccharidosis IPHASE1_PHASE2 · COMPLETED · started Sep 1, 2020ClinicalTrials.gov NCT04227600 · fetched Nov 12, 2026